TW202506187A - 葡聚糖與tlr7促效劑之複合體 - Google Patents
葡聚糖與tlr7促效劑之複合體 Download PDFInfo
- Publication number
- TW202506187A TW202506187A TW113113616A TW113113616A TW202506187A TW 202506187 A TW202506187 A TW 202506187A TW 113113616 A TW113113616 A TW 113113616A TW 113113616 A TW113113616 A TW 113113616A TW 202506187 A TW202506187 A TW 202506187A
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- compound
- group
- bonded
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-065007 | 2023-04-12 | ||
| JP2023065007 | 2023-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202506187A true TW202506187A (zh) | 2025-02-16 |
Family
ID=93059496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113113616A TW202506187A (zh) | 2023-04-12 | 2024-04-11 | 葡聚糖與tlr7促效劑之複合體 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPWO2024214771A1 (https=) |
| CN (1) | CN121311513A (https=) |
| TW (1) | TW202506187A (https=) |
| WO (1) | WO2024214771A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011008A (en) * | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
| WO2017061532A1 (ja) * | 2015-10-07 | 2017-04-13 | 大日本住友製薬株式会社 | ピリミジン化合物 |
| CN107304232B (zh) * | 2017-05-20 | 2020-07-28 | 杭州师范大学 | 一种葡聚糖/吲哚美辛接枝物的合成方法与应用 |
| US10722591B2 (en) * | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
-
2024
- 2024-04-11 CN CN202480039214.1A patent/CN121311513A/zh active Pending
- 2024-04-11 WO PCT/JP2024/014657 patent/WO2024214771A1/ja not_active Ceased
- 2024-04-11 JP JP2025514006A patent/JPWO2024214771A1/ja active Pending
- 2024-04-11 TW TW113113616A patent/TW202506187A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121311513A (zh) | 2026-01-09 |
| JPWO2024214771A1 (https=) | 2024-10-17 |
| WO2024214771A1 (ja) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6970859B2 (ja) | TAMおよびMETキナーゼの阻害薬としてのピラゾロ[3,4−b]ピリジン化合物 | |
| JP7085985B2 (ja) | 悪性腫瘍治療用製剤及び組成物 | |
| EP3373932B1 (en) | Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof | |
| JP7719072B2 (ja) | 三分岐n-アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法 | |
| WO2022262516A1 (zh) | 连接子及其缀合物 | |
| US20240033266A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| US20240009321A1 (en) | Immunogenic nanovesicles for cancer immunotherapy | |
| WO2015117551A1 (zh) | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 | |
| WO2024017229A1 (zh) | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 | |
| WO2022138944A1 (ja) | Swi/snf複合体機能異常がんの合成致死性に基づく治療法 | |
| CN101302199B (zh) | 桂德霉素及其在制备抗肿瘤药物中的应用 | |
| CN112010839A (zh) | 靶向丝/苏氨酸激酶抑制剂的晶型 | |
| ES2458818T3 (es) | Métodos para evaluar la actividad de una composición de polisacárido | |
| TW202506187A (zh) | 葡聚糖與tlr7促效劑之複合體 | |
| JP6461088B2 (ja) | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 | |
| WO2020105701A1 (ja) | 新規ポリマー-活性薬物-コンジュゲート及びその用途 | |
| CN120676939A (zh) | Pi3k抑制剂及其制备和使用方法 | |
| WO2020204173A1 (ja) | 水溶性アジュバントおよびそれを含有する組成物 | |
| WO2015125640A1 (ja) | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 | |
| RU2697551C2 (ru) | Новые производные peg | |
| WO2023008462A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
| CN119770678B (zh) | 一种葡萄柚细胞外囊泡负载三功能四价铂化合物的纳米药物及其制备方法和应用 | |
| WO2025263617A1 (ja) | コレステロールとtlr7アゴニストのコンジュゲート体およびそれを含む医薬組成物 | |
| EP3747909B1 (en) | Anticancer agent | |
| WO2026054677A1 (en) | Trastuzumab-drug conjugate |